-+ 0.00%
-+ 0.00%
-+ 0.00%

ASCLETIS ANNOUNCES POSITIVE RESULTS FROM 28-DAY PROOF-OF-CONCEPT CLINICAL STUDY IN U.S. FOR ASC50, A FIRST-IN-CLASS AND BEST-IN-CLASS ORAL SMALL MOLECULE IL-17A INHIBITOR FOR THE TREATMENT OF PLAQUE PSORIASIS

Reuters·09/29/2026 00:00:00

Please log in to view news